SCHEMBL23326256

SCHEMBL23326256

C[C@@H](Nc1c(-c2nc3ccc(N4CCN(C)CC4)cc3[nH]2)c(=O)[nH]c2ccccc12)c1ccccn1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR3 P22607 2/20 0.68
FGFR1 P11362 18/20 0.64
PDGFRB P09619 16/20 0.64
KDR P35968 16/20 0.64
FLT1 P17948 5/20 0.64
LCK P06239 2/20 0.52
FLT3 P36888 2/20 0.52
MAP4K1 Q92918 2/20 0.52
PLK4 O00444 1/20 0.52
STK25 O00506 1/20 0.52
CIT O14578 1/20 0.52
RIOK3 O14730 1/20 0.52
CHEK1 O14757 1/20 0.52
GAK O14976 1/20 0.52
CHUK O15111 1/20 0.52
MUSK O15146 1/20 0.52
EPHB6 O15197 1/20 0.52
PDPK1 O15530 1/20 0.52
MAP3K13 O43283 1/20 0.52
DAPK3 O43293 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20625528 1.00 FGFR3 (0.68) FGFR3FGFR1PDGFRBKDRFLT1
SCHEMBL20625529 1.00 FGFR3 (0.68) FGFR3FGFR1PDGFRBKDRFLT1
SCHEMBL20625447 0.94 FGFR3 (0.60) FGFR3FGFR1PDGFRBKDRFLT1
SCHEMBL23326253 0.94 FGFR3 (0.60) FGFR3FGFR1PDGFRBKDRFLT1
SCHEMBL20625616 0.92 FGFR1 (0.62) FGFR3FGFR1PDGFRBKDRFLT1
SCHEMBL23326078 0.92 FGFR1 (0.62) FGFR3FGFR1PDGFRBKDRFLT1
SCHEMBL23326198 0.92 FGFR3 (0.64) FGFR3FGFR1PDGFRBKDRFLT1
SCHEMBL20624951 0.92 FGFR3 (0.64) FGFR3FGFR1PDGFRBKDRFLT1
SCHEMBL20625272 0.92 FGFR3 (0.58) FGFR3FGFR1PDGFRBKDRFLT1
SCHEMBL20625271 0.92 FGFR3 (0.58) FGFR3FGFR1PDGFRBKDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111032643-B Quinolinone compounds 詹森药业有限公司 2023-05-30 CN disclosed
US-11384075-B2 Quinolinone compounds JANSSEN PHARMACEUTICA NV (BE) 2022-07-12 US disclosed
US-11384075-B2 Quinolinone compounds JANSSEN PHARMACEUTICA NV (BE) 2022-07-12 US disclosed
US-20210139470-A1 New Quinolinone Compounds JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2021-05-13 US disclosed
US-20210139470-A1 New Quinolinone Compounds JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2021-05-13 US disclosed
CN-111032643-A Quinolinone compounds 詹森药业有限公司 2020-04-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139470-A1 New Quinolinone Compounds FGFR1, FGFR2, FGFR3 FGFR3 3/4885FGFR1 1/4885PDGFRB 31/4885
US-11384075-B2 Quinolinone compounds FGFR1, FGFR2, FGFR3 FGFR3 3/4885FGFR1 1/4885PDGFRB 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.